Back to Search

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

  • Protocol Number: 201909144
  • Principal Investigator: Van Tine, Brian
  • Cancer Types: Early Phase, Gene & Cellular Immunotherapy

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions